Partnership to Ensure Gene-modified Cell Therapies for Ovarian Cancer Trials

Partnership to Ensure Gene-modified Cell Therapies for Ovarian Cancer Trials
Senti Biosciences is working with RoosterBio to ensure a quality supply of its candidate gene-modified cell therapies for ovarian cancer and other solid tumors, with a goal of bringing them into clinical testing. These investigative therapies are based on the replacement, inactivation, or introduction of genes into cells that were cultivated or modified outside the body. The modifications can be “tailored” for a specific condition and person. Engineered cells are then injected into a patient, where they are intended to slow and possibly stop disease progression. “Gene-modified cell therapies are one of the most important segments in our industry, and we are excited to help Senti Biosciences accelerate its technology into the clinic,” Jon A. Rowley, PhD, RoosterBio’s founder and chief product officer, said in a press release.  The agreement refers to Senti’s gene circuit technology — a type of gene-modified cell therapy that uses constructs of multiple genes. These constructs follow a computer-like logic to program cells to respond, adapt, and make decisions based on the inputs they receive from proteins, hormones, and other molecules. Senti’s gene circuits are designed to create broad and sustained anti-tumor immune responses. They can also be used to target and eliminate cancer cells with precision, leaving the healthy tissue unharmed, the company reports. “Gene circuits have the potential to lead the next wave of cell and gene therapies to address the high unmet need in difficult-to-treat cancers, such as ovarian cancer” said Philip Lee, PhD, Senti’s chief operating officer and co-founder. The Senti-RoosterBio collaboration will use human mesenchymal stem/stromal cells (hMSCs) to carry the gene circuits. hMSCs are a type o
Subscribe or to access all post and page content.